Clinical trial
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With…
NCT04468659 · Eisai Inc., Industry · Active, not recruiting
Key facts
| NCT number | NCT04468659 |
|---|---|
| Title | AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid |
| Official title | AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical… |
| Lead sponsor | Eisai Inc., Industry |
| Collaborators | Alzheimer's Clinical Trials Consortium Biogen Industry National Institute on Aging (NIA) NIH |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Lecanemab, Placebo |
| Enrollment | 1,400 |
| Start date | Jul 14, 2020 |
| Primary completion | Dec 21, 2028 |
| Completion | Jan 16, 2031 |
| First posted | Jul 13, 2020 |
| Last update posted | Jan 12, 2026 |
| Countries | Australia, Canada, Japan, Singapore, Spain, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: